A Phase 2 interventional study of placebo and Pregabalin in Restless Legs Syndrome, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 25 sites in 4 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2021-02-10.
Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 107 studies in Restless Legs Syndrome with a site in United States — 9 open to participants now, 13 under way, none of them phase 3. Restless Legs Syndrome · United States.
Among the 107 studies in Restless Legs Syndrome with a site in United States, this one is the 26th largest by enrollment of the 95 interventional ones that give a count, is one of 6 that started in 2008, is one of 16 in phase 2, and was the 30th registered.
259 studies on the registry are indexed under Restless Legs Syndrome; 38 are open to participants now.
Browse Restless Legs Syndrome studies →9 of the 107 studies in Restless Legs Syndrome with a site in United States are open now. Recruiting first, the newest first:
Noctrix Health, Inc. · Sites in United States
Ages 21+
Rhode Island Hospital · Sites in United States
Ages 18+ · Women only
University of Alabama at Birmingham · Sites in United States
Ages 18+ · Healthy volunteers
HBC Immunology Inc · Sites in United States
Ages 18–60
Stanford University · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 25 Restless Legs Syndrome studies recruiting now, 10 (40%) set no upper age limit and 12 (48%) stop at 75 or younger; none take children under 18; 10 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
107 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 23 · Phase 3 21 · Phase 4 18
First in 1995; this study’s year is marked. 6 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 137 is above the median of 53 across 200 interventional studies indexed under Restless Legs Syndrome.
Median enrollment 46 across the 95 interventional studies, 72 across the 12 observational. Of the 83 that completed or were terminated, 35 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
50 of 107 have an industry lead sponsor. The 10 most frequent:
This study is registered under Pfizer's Upjohn has merged with Mylan to form Viatris Inc., one of the names counted as Viatris Inc.. Under that name alone:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. is the lead sponsor of 434 studies on the registry; none are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 8 (89%) have results posted.
Viatris Inc. has 4 studies filed under Restless Legs Syndrome — fewer than ten, so there is no comparison to draw.
3 of the studies in Restless Legs Syndrome with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02670161Endeavor HealthQuality Improvement and Practice Based Research in Neurology Using the EMR | 2026-12 |
| NCT07675109Noctrix Health, Inc.Optimizing Extended-Duration (XD-) TOMAC Therapy for Restless Legs Syndrome (RLS) | 2026-12 |
| NCT07061470Hugo W. Moser Research Institute at Kennedy Krieger, Inc.A Clinical Trial of Iron Supplementation for Youth With ADHD and Restless Sleep | 2027-07-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 107 studies in Restless Legs Syndrome with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To test the effectiveness and tolerability of Lyrica at various dose levels in RLS patients
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Placebo
Drug: placebo
investigational treatment
Drug: Pregabalin
investigational treatment
Drug: Pregabalin
investigational treatment
Drug: Pregabalin
investigational treatment
Drug: Pregabalin
investigational treatment
Drug: Pregabalin
Placebo control (capsule), once a day, 1- 3 hours before bedtime for 6 weeks
Also known as: Sugar pill
50 mg (capsule) per day, 1 - 3 hours before bedtime for 6 weeks
Also known as: Lyrica, PD 0144723; CI-1008
100 mg (capsule) per day, 1 - 3 hours before bedtime for 6 weeks
Also known as: Lyrica, PD 0144723; CI-1008
150 mg (capsule) per day, 1 - 3 hours before bedtime for 6 weeks
Also known as: Lyrica, PD 0144723; CI-1008
300 mg (capsule) per day, 1 - 3 hours before bedtime for 6 weeks
Also known as: Lyrica, PD 0144723; CI-1008
450 mg (capsule) per day, 1 - 3 hours before bedtime for 6 weeks
Also known as: Lyrica, PD 0144723; CI-1008
Change From Baseline in Restless Leg Syndrome (RLS) International Restless Leg Group Symptom Severity Rating Scale (IRLS) Total Score at Week 6
IRLS: Subject-rated instrument to assess RLS symptom severity and impact on daily living; 10 items yielding 2 subscale scores and 1 global (total) score. Subscale scores: symptom severity (6 items) and impact on daily living (3 items), with item 5 (daytime somnolence due to RLS) loaded equally on both subscales. Global score: calculated from all 10 items. Subscale score ranges: symptom severity 0-24, impact of daily living 0-12; global score range: 0-40. Lower scores reflect lower severity and better quality of life. Change from baseline = score at observation minus score at baseline.
Time frame: Baseline, Week 6
Number of Subjects Responding to Treatment as Assessed by the Clinical Global Impression - Improvement Scale (CGI-I)
Clinical Global Impression - Improvement Scale (CGI-I): 7-point clinician rated scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved), 2 (much improved), or 3 (minimally improved) on the scale. Higher score = more affected. Number of subjects responding to treatment at Week 6 with respect to dose level. CGI-I Responders = subjects who reported CGI-I scores of very much improved or much improved.
Time frame: Week 6
Number of Subjects With Categorical Scores on the Clinical Global Impression - Severity Scale (CGI-S)
CGI-S Scale: 7-point clinician rated scale to assess severity of subject's current illness state; range: 1 (normal - not ill at all) to 7 (among the most extremely ill patients). Higher score = more affected.
Time frame: Baseline, Week 1, Week 2, Week 4, Week 6, Last Observation Carried Forward (LOCF)
Subjective Sleep Questionnaire (SSQ): Latency Subscale; Observed Change From Baseline
Subjective Sleep Questionnaire (SSQ): subject-rated instrument used to assess sleep behavior; measures sleep quantity and quality. Comprised of 5 items yielding 5 subscale scores: latency, hours of sleep, number of awakenings, total wake time after sleep onset, and quality of sleep. Latency subscale (time to fall asleep \[in minutes\]): numerical rating completed by the subject 30 minutes after waking; recall period is the night before. Lower score reflects greater ease (shorter time) in falling asleep. Change from baseline = score at observation minus score at baseline.
Time frame: Baseline, Week 1, Week 2, Week 3, Week 4, Week 5, Week 6
Subjective Sleep Questionnaire: Hours of Sleep Subscale; Observed Change From Baseline
Subjective Sleep Questionnaire (SSQ): subject-rated instrument used to assess sleep behavior; measures sleep quantity and quality. Comprised of 5 items yielding 5 subscale scores: latency, hours of sleep, number of awakenings, total wake time after sleep onset, and quality of sleep. Hours of sleep subscale reflects change in hours of sleep from baseline. Numerical rating completed by the subject 30 minutes after waking; recall period is the night before.
Time frame: Baseline, Week 1, Week 2, Week 3, Week 4, Week 5, Week 6
Subjective Sleep Questionnaire: Number of Awakenings Subscale; Observed Change From Baseline
Subjective Sleep Questionnaire (SSQ): subject-rated instrument used to assess sleep behavior; measures sleep quantity and quality. Comprised of 5 items yielding 5 subscale scores: latency, hours of sleep, number of awakenings, total wake time after sleep onset, and quality of sleep. Number of awakenings subscale: numerical rating completed by the subject 30 minutes after waking; recall period is the night before. Fewer awakenings reflect better quality of sleep. Change from baseline = score at observation minus score at baseline.
Time frame: Baseline, Week 1, Week 2, Week 3, Week 4, Week 5, Week 6
Subjective Sleep Questionnaire: Total Wake Time After Sleep Onset Subscale; Observed Change From Baseline
Subjective Sleep Questionnaire (SSQ): subject-rated instrument used to assess sleep behavior; measures sleep quantity and quality. Comprised of 5 items yielding 5 subscale scores: latency, hours of sleep, number of awakenings, total wake time after sleep onset, and quality of sleep. Total wake time after sleep onset subscale (in minutes): numerical rating completed by the subject 30 minutes after waking; recall period is the night before. Reduction = improvement. Change from baseline = score at observation minus score at baseline.
Time frame: Baseline, Week 1, Week 2, Week 3, Week 4, Week 5, Week 6
Subjective Sleep Questionnaire: Quality of Sleep Subscale; Observed Change From Baseline
Subjective Sleep Questionnaire (SSQ): subject-rated instrument used to assess sleep behavior; measures sleep quantity and quality. Comprised of 5 items yielding 5 subscale scores: latency, hours of sleep, number of awakenings, total wake time after sleep onset, and quality of sleep. Quality of sleep subscale: visual analog scale ranging from 1 (very poor) to 100 (excellent) completed by the subject 30 minutes after waking; recall period is the night before. Change from baseline = score at observation minus score at baseline.
Time frame: Baseline, Week 1, Week 2, Week 3, Week 4, Week 5, Week 6
Medical Outcomes Study - Sleep Scale (MOSS-SS): Sleep Disturbance Subscale; Observed Change From Baseline
MOS-SS: subject-rated instrument used to assess the key constructs of sleep quantity and quality over the past week; comprised of 12 items yielding 7 subscale scores and 2 composite index scores. Sleep Disturbance Subscale score (4 items): range 0-100; lower score indicates less disturbance. Change from baseline = score at observation minus score at baseline.
Time frame: Baseline, Week 1, Week 2, Week 4, Week 6
Medical Outcomes Study - Sleep Scale (MOSS-SS): Snoring Subscale; Observed Change From Baseline
MOS-SS: subject-rated instrument used to assess the key constructs of sleep; assesses sleep quantity and quality over the past week. Comprised of 12 items yielding 7 subscale scores and 2 composite index scores. Snoring Subscale score (1 item): range 0-100, lower score indicates less snoring. Change from baseline = score at observation minus score at baseline.
Time frame: Baseline, Week 1, Week 2, Week 4, Week 6
Medical Outcomes Study - Sleep Scale (MOSS-SS): Awaken Short of Breath or With Headache Subscale; Observed Change From Baseline
MOS-SS: subject-rated instrument used to assess the key constructs of sleep over the past week ; comprised of 12 items yielding 7 subscale scores and 2 composite index scores. Awaken Short of Breath or with Headache subscale score range: 0-100; lower score indicates less difficulty. Change from baseline = score at observation minus score at baseline.
Time frame: Baseline, Week 1, Week 2, Week 4, Week 6
Medical Outcomes Study - Sleep Scale (MOSS-SS): Sleep Adequacy Subscale; Observed Change From Baseline
MOS-SS: subject-rated instrument used to assess the key constructs of sleep; assesses sleep quantity and quality and is comprised 12 items yielding 7 subscale scores and 2 composite index scores. Sleep Adequacy Subscale score range: 0-100; higher scores indicates greater sleep adequacy. Change from baseline = score at observation minus score at baseline.
Time frame: Baseline, Week 1, Week 2, Week 4, Week 6
Medical Outcomes Study - Sleep Scale (MOSS-SS): Somnolence Subscale; Observed Change From Baseline
MOS-SS: subject-rated instrument used to assess the key constructs of sleep over the past week; assesses sleep quantity and quality and is comprised 12 items yielding 7 subscale scores and 2 composite index scores. Sleep Somnolence Subscale score range: 0-100; higher score indicates less somnolence. Change from baseline = score at observation minus score at baseline.
Time frame: Baseline,, Week 1, Week 2, Week 4, Week 6
Medical Outcomes Study - Sleep Scale (MOSS-SS): Sleep Quantity Subscale; Observed Change From Baseline
MOS-SS: subject-rated instrument used to assess the key constructs of sleep over the past week; assesses sleep quantity and quality and is comprised 12 items yielding 7 subscale scores and 2 composite index scores. Sleep Quantity (1 item) subscale score range: 0-24 hours. Change from Baseline in number of hours slept. Change from baseline = score at observation minus score at baseline.
Time frame: Baseline,, Week 1, Week 2, Week 4, Week 6
Medical Outcomes Study - Sleep Scale (MOSS-SS): 6-Item Sleep Problems Index; Observed Change From Baseline
MOS-SS: subject-rated instrument used to assess the key constructs of sleep over the past week; assesses sleep quantity and quality and is comprised 12 items yielding 7 subscale scores and 2 composite index scores. Sleep Problems Index I (6 items): composite index score range 0-100; lower score indicates fewer sleep problems. Change from baseline = score at observation minus score at baseline.
Time frame: Baseline, Week 1, Week 2, Week 4, Week 6
Medical Outcomes Study - Sleep Scale (MOSS-SS): 9-Item Sleep Problems Index; Observed Change From Baseline
MOS-SS: subject-rated instrument used to assess the key constructs of sleep over the past week; assesses sleep quantity and quality and is comprised 12 items yielding 7 subscale scores and 2 composite index scores. Composite index scores are sleep problems Index I (6 items) and sleep problems Index II (9 items). 9-Item Sleep Problems Index range: 0-100; lower score indicates fewer sleep problems. Change from baseline = score at observation minus score at baseline.
Time frame: Baseline, Week 1, Week 2, Week 4, Week 6
Medical Outcomes Study - Sleep Scale (MOSS-SS): Optimal Sleep; Observed Cases Summarized by Week
MOS-SS: subject-rated instrument used to assess the key constructs of sleep over the past week; assesses sleep quantity and quality and is comprised 12 items yielding 7 subscale scores and 2 composite index scores. Optimal Sleep subscale is derived from sleep quantity average hours of sleep each night during the past week. Number of subjects with response: YES (Optimal) if sleep quantity was 7 or 8 hours of sleep per night.
Time frame: Week 1, Week 2, Week 4, Week 6
Restless Leg Syndrome - Quality of Life Scale (RLS-QoL): Change From Baseline to Week 6
RLS QoL: subject-rated instrument used to assess the impact of RLS on quality of life and health status function (symptom severity, daily activity, social functioning, sleep, concentrating and decision making, traveling, sexual activity, and work) yielding a summary score ranging from 0-100. Higher scores reflect better quality of life. Recall period is the month prior to the assessment. Change from baseline = score at observation minus score at baseline.
Time frame: Baseline, Week 6
Medical Outcomes Study Short Form 36 (SF-36): Change From Baseline to Week 6
Subject-rated measure of health status comprised of 36 items: 8 subscale scores (physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health), 2 summary scores (physical component and mental component), and a self-evaluated change in health status. Subscale and summary scores range: 0-100. Higher subscale and summary scores = better health status. Recall period: month prior to the assessment. Change from baseline = score at observation minus score at baseline.
Time frame: Baseline, Week 6
Medical Outcomes Study Short Form 36 (SF-36); Number of Subjects With Self-Evaluated Change in Health Status Scores
Subject-rated measure of health status comprised of 36 items: 8 subscale scores (physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health), 2 summary scores (physical component and mental component), and a self-evaluated change in health status. Self-evaluated change in health status: 5 Likert-type response categories ranging from "much worse now" to much better now." Recall period: month prior to the assessment.
Time frame: Baseline, Week 6
| Milestone | Placebo | Pregabalin 50 mg | Pregabalin 100 mg | Pregabalin 150 mg | Pregabalin 300 mg | Pregabalin 450 mg |
|---|---|---|---|---|---|---|
| Started | 23 | 22 | 23 | 22 | 24 | 23 |
| Completed | 21 | 20 | 22 | 17 | 23 | 18 |
| Not completed | 2 | 2 | 1 | 5 | 1 | 5 |
| Withdrew: Adverse event | 1 | 2 | 0 | 5 | 1 | 2 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Reason unspecified | 1 | 0 | 1 | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 1 |
IRLS: Subject-rated instrument to assess RLS symptom severity and impact on daily living; 10 items yielding 2 subscale scores and 1 global (total) score. Subscale scores: symptom severity (6 items) and impact on daily living (3 items), with item 5 (daytime somnolence due to RLS) loaded equally on both subscales. Global score: calculated from all 10 items. Subscale score ranges: symptom severity 0-24, impact of daily living 0-12; global score range: 0-40. Lower scores reflect lower severity and better quality of life. Change from baseline = score at observation minus score at baseline.
| scores on scale | Placebo | Pregabalin 50 mg | Pregabalin 100 mg | Pregabalin 150 mg | Pregabalin 300 mg | Pregabalin 450 mg |
|---|---|---|---|---|---|---|
| Change From Baseline in Restless Leg Syndrome (RLS) International Restless Leg Group Symptom Severity Rating Scale (IRLS) Total Score at Week 6 | -7.73 ± 1.720 | -11.83 ± 1.771 | -11.76 ± 1.694 | -16.02 ± 1.865 | -12.89 ± 1.713 | -16.26 ± 1.771 |
Clinical Global Impression - Improvement Scale (CGI-I): 7-point clinician rated scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved), 2 (much improved), or 3 (minimally improved) on the scale. Higher score = more affected. Number of subjects responding to treatment at Week 6 with respect to dose level. CGI-I Responders = subjects who reported CGI-I scores of very much improved or much improved.
| participants | Placebo | Pregabalin 50 mg | Pregabalin 100 mg | Pregabalin 150 mg | Pregabalin 300 mg | Pregabalin 450 mg |
|---|---|---|---|---|---|---|
| Week 6: Responders (n=21, 20, 22, 18, 23, 20) | 13 | 12 | 15 | 11 | 17 | 18 |
| Week 6: Non-Responders | 8 | 8 | 7 | 7 | 6 | 2 |
CGI-S Scale: 7-point clinician rated scale to assess severity of subject's current illness state; range: 1 (normal - not ill at all) to 7 (among the most extremely ill patients). Higher score = more affected.
| participants | Placebo | Pregabalin 50 mg | Pregabalin 100 mg | Pregabalin 150 mg | Pregabalin 300 mg | Pregabalin 450 mg |
|---|---|---|---|---|---|---|
| Baseline: Normal, Not at All Ill | 0 | 0 | 0 | 0 | 0 | 0 |
| Baseline: Borderline, Mentally Ill | 0 | 0 | 0 | 0 | 0 | 0 |
| Baseline: Mildly Ill | 1 | 1 | 2 | 4 | 2 | 2 |
| Baseline: Moderately Ill | 6 | 9 | 8 | 5 | 11 | 6 |
| Baseline: Markedly Ill | 7 | 8 | 7 | 5 | 3 | 5 |
| Baseline: Severely Ill | 8 | 3 | 6 | 7 | 8 | 10 |
| Baseline: Among the Most Extremely Ill | 1 | 1 | 0 | 1 | 0 | 0 |
| Week 1: Normal, Not at All Ill | 1 | 1 | 1 | 1 | 0 | 3 |
| Week 1: Borderline, Mentally Ill | 0 | 1 | 1 | 1 | 4 | 2 |
| Week 1: Mildly Ill | 4 | 6 | 5 | 8 | 5 | 7 |
| Week 1: Moderately Ill | 10 | 8 | 5 | 7 | 6 | 8 |
| Week 1: Markedly Ill | 4 | 3 | 5 | 1 | 3 | 2 |
| Week 1: Severely Ill | 4 | 2 | 3 | 2 | 5 | 1 |
| Week 1: Among the Most Extremely Ill | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 2: Normal, Not at All Ill | 0 | 2 | 1 | 2 | 3 | 7 |
| Week 2: Borderline, Mentally Ill | 3 | 4 | 2 | 3 | 6 | 2 |
| Week 2: Mildly Ill | 10 | 5 | 9 | 7 | 4 | 8 |
| Week 2: Moderately Ill | 3 | 5 | 5 | 6 | 5 | 3 |
| Week 2: Markedly Ill | 3 | 3 | 4 | 0 | 3 | 0 |
| Week 2: Severely Ill | 3 | 1 | 1 | 1 | 1 | 0 |
| Week 2: Among the Most Extremely Ill | 1 | 0 | 0 | 0 | 0 | 0 |
| Week 4: Normal, Not at All Ill | 1 | 2 | 2 | 5 | 4 | 8 |
| Week 4: Borderline, Mentally Ill | 4 | 2 | 2 | 2 | 6 | 5 |
| Week 4: Mildly Ill | 8 | 7 | 11 | 5 | 4 | 4 |
| Week 4: Moderately Ill | 4 | 6 | 6 | 5 | 5 | 2 |
| Week 4: Markedly Ill | 3 | 2 | 1 | 1 | 2 | 1 |
| Week 4: Severely Ill | 2 | 2 | 1 | 1 | 2 | 0 |
| Week 4: Among the Most Extremely Ill | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 6: Normal, Not at All Ill | 1 | 3 | 4 | 4 | 6 | 7 |
| Week 6: Borderline, Mentally Ill | 3 | 3 | 4 | 4 | 4 | 5 |
| Week 6: Mildly Ill | 11 | 6 | 7 | 7 | 7 | 6 |
| Week 6: Moderately Ill | 2 | 5 | 5 | 3 | 1 | 1 |
| Week 6: Markedly Ill | 2 | 2 | 2 | 0 | 4 | 1 |
| Week 6: Severely Ill | 2 | 1 | 0 | 0 | 1 | 0 |
| Week 6: Among the Most Extremely Ill | 0 | 0 | 0 | 0 | 0 | 0 |
| LOCF: Normal | 1 | 3 | 4 | 4 | 6 | 7 |
| LOCF: Borderline, Mentally Ill | 3 | 3 | 4 | 4 | 4 | 6 |
| LOCF: Mildly Ill | 12 | 6 | 7 | 9 | 7 | 7 |
| LOCF: Moderately Ill | 2 | 6 | 5 | 5 | 1 | 1 |
| LOCF: Markedly Ill | 2 | 2 | 2 | 0 | 4 | 1 |
| LOCF: Severely Ill | 2 | 2 | 1 | 0 | 2 | 1 |
| LOCF: Among the Most Extremely Ill | 1 | 0 | 0 | 0 | 0 | 0 |
Subjective Sleep Questionnaire (SSQ): subject-rated instrument used to assess sleep behavior; measures sleep quantity and quality. Comprised of 5 items yielding 5 subscale scores: latency, hours of sleep, number of awakenings, total wake time after sleep onset, and quality of sleep. Latency subscale (time to fall asleep \[in minutes\]): numerical rating completed by the subject 30 minutes after waking; recall period is the night before. Lower score reflects greater ease (shorter time) in falling asleep. Change from baseline = score at observation minus score at baseline.
| minutes | Placebo | Pregabalin 50 mg | Pregabalin 100 mg | Pregabalin 150 mg | Pregabalin 300 mg | Pregabalin 450 mg |
|---|---|---|---|---|---|---|
| Week 1 | -9.8 ± 5.60 | -16.3 ± 5.76 | -13.2 ± 5.60 | -10.4 ± 5.76 | -9.1 ± 5.65 | -20.2 ± 5.62 |
| Week 2 | -8.9 ± 5.60 | -20.7 ± 5.84 | -17.2 ± 5.65 | -16.3 ± 6.00 | -13.0 ± 5.71 | -34.3 ± 5.69 |
| Week 3 | -14.6 ± 5.71 | -18.9 ± 5.90 | -13.1 ± 5.60 | -17.8 ± 6.00 | -17.8 ± 5.71 | -33.7 ± 5.88 |
| Week 4 | -13.6 ± 5.66 | -20.4 ± 5.90 | -20.4 ± 5.60 | -18.2 ± 6.00 | -18.2 ± 5.71 | -37.1 ± 5.82 |
| Week 5 | -15.9 ± 5.71 | -26.8 ± 5.90 | -17.6 ± 5.60 | -24.0 ± 6.07 | -13.4 ± 5.71 | -36.1 ± 5.82 |
| Week 6 | -12.4 ± 5.71 | -25.4 ± 5.90 | -19.5 ± 5.65 | -25.1 ± 6.14 | -10.1 ± 5.71 | -34.9 ± 5.82 |
Subjective Sleep Questionnaire (SSQ): subject-rated instrument used to assess sleep behavior; measures sleep quantity and quality. Comprised of 5 items yielding 5 subscale scores: latency, hours of sleep, number of awakenings, total wake time after sleep onset, and quality of sleep. Hours of sleep subscale reflects change in hours of sleep from baseline. Numerical rating completed by the subject 30 minutes after waking; recall period is the night before.
| hours | Placebo | Pregabalin 50 mg | Pregabalin 100 mg | Pregabalin 150 mg | Pregabalin 300 mg | Pregabalin 450 mg |
|---|---|---|---|---|---|---|
| Week 1 | 0.23 ± 0.177 | 0.57 ± 0.183 | 0.29 ± 0.177 | 0.55 ± 0.182 | 0.45 ± 0.177 | 0.72 ± 0.178 |
| Week 2 | 0.36 ± 0.177 | 0.65 ± 0.186 | 0.52 ± 0.179 | 0.81 ± 0.192 | 0.76 ± 0.180 | 1.07 ± 0.181 |
| Week 3 | 0.36 ± 0.182 | 0.61 ± 0.188 | 0.53 ± 0.177 | 0.89 ± 0.192 | 0.72 ± 0.180 | 1.32 ± 0.189 |
| Week 4 | 0.27 ± 0.180 | 0.81 ± 0.188 | 0.46 ± 0.177 | 0.93 ± 0.192 | 0.65 ± 0.180 | 1.03 ± 0.187 |
| Week 5 | 0.37 ± 0.182 | 1.03 ± 0.188 | 0.43 ± 0.177 | 0.97 ± 0.195 | 0.61 ± 0.180 | 1.43 ± 0.187 |
| Week 6 | 0.19 ± 0.182 | 0.84 ± 0.188 | 0.42 ± 0.179 | 0.95 ± 0.198 | 0.44 ± 0.180 | 1.11 ± 0.187 |
Subjective Sleep Questionnaire (SSQ): subject-rated instrument used to assess sleep behavior; measures sleep quantity and quality. Comprised of 5 items yielding 5 subscale scores: latency, hours of sleep, number of awakenings, total wake time after sleep onset, and quality of sleep. Number of awakenings subscale: numerical rating completed by the subject 30 minutes after waking; recall period is the night before. Fewer awakenings reflect better quality of sleep. Change from baseline = score at observation minus score at baseline.
| awakenings | Placebo | Pregabalin 50 mg | Pregabalin 100 mg | Pregabalin 150 mg | Pregabalin 300 mg | Pregabalin 450 mg |
|---|---|---|---|---|---|---|
| Week 1 | -0.5 ± 0.21 | -0.9 ± 0.21 | -1.0 ± 0.21 | -1.2 ± 0.21 | -0.7 ± 0.21 | -0.8 ± 0.21 |
| Week 2 | -0.7 ± 0.21 | -1.0 ± 0.22 | -1.3 ± 0.21 | -1.3 ± 0.23 | -1.3 ± 0.21 | -1.1 ± 0.21 |
| Week 3 | -0.7 ± 0.21 | -1.0 ± 0.22 | -1.0 ± 0.21 | -1.3 ± 0.23 | -1.2 ± 0.21 | -1.4 ± 0.22 |
| Week 4 | -0.9 ± 0.21 | -1.1 ± 0.22 | -1.2 ± 0.21 | -1.5 ± 0.23 | -1.1 ± 0.21 | -1.2 ± 0.22 |
| Week 5 | -0.8 ± 0.21 | -1.3 ± 0.22 | -1.0 ± 0.21 | -1.6 ± 0.23 | -1.2 ± 0.21 | -1.5 ± 0.22 |
| Week 6 | -1.0 ± 0.21 | -1.0 ± 0.22 | -1.1 ± 0.21 | -1.5 ± 0.23 | -1.0 ± 0.21 | -1.2 ± 0.22 |
Subjective Sleep Questionnaire (SSQ): subject-rated instrument used to assess sleep behavior; measures sleep quantity and quality. Comprised of 5 items yielding 5 subscale scores: latency, hours of sleep, number of awakenings, total wake time after sleep onset, and quality of sleep. Total wake time after sleep onset subscale (in minutes): numerical rating completed by the subject 30 minutes after waking; recall period is the night before. Reduction = improvement. Change from baseline = score at observation minus score at baseline.
| minutes | Placebo | Pregabalin 50 mg/Day | Pregabalin 100 mg/Day | Pregabalin 150 mg/Day | Pregabalin 300 mg/Day | Pregablin 450 mg/Day |
|---|---|---|---|---|---|---|
| Week 1 | -23.8 ± 7.44 | -37.9 ± 7.66 | -28.5 ± 7.47 | -29.0 ± 7.81 | -32.2 ± 7.58 | -32.6 ± 7.46 |
| Week 2 | -29.5 ± 7.44 | -47.0 ± 7.79 | -36.5 ± 7.55 | -41.9 ± 8.23 | -39.8 ± 7.68 | -46.3 ± 7.57 |
| Week 3 | -34.3 ± 7.62 | -51.4 ± 8.01 | -32.0 ± 7.47 | -45.9 ± 8.23 | -42.3 ± 7.59 | -42.9 ± 7.89 |
| Week 4 | -30.4 ± 7.53 | -50.7 ± 8.01 | -36.5 ± 7.47 | -46.0 ± 8.23 | -43.6 ± 7.68 | -46.8 ± 7.79 |
| Week 5 | -28.7 ± 7.62 | -55.4 ± 8.01 | -30.7 ± 7.47 | -59.6 ± 8.36 | -42.5 ± 7.59 | -55.1 ± 7.79 |
| Week 6 | -34.2 ± 7.62 | -57.0 ± 7.90 | -34.2 ± 7.55 | -54.0 ± 8.49 | -41.1 ± 7.68 | -55.5 ± 7.89 |
Subjective Sleep Questionnaire (SSQ): subject-rated instrument used to assess sleep behavior; measures sleep quantity and quality. Comprised of 5 items yielding 5 subscale scores: latency, hours of sleep, number of awakenings, total wake time after sleep onset, and quality of sleep. Quality of sleep subscale: visual analog scale ranging from 1 (very poor) to 100 (excellent) completed by the subject 30 minutes after waking; recall period is the night before. Change from baseline = score at observation minus score at baseline.
| scores on scale | Placebo | Pregabalin 50 mg | Pregabalin 100 mg | Pregabalin 150 mg | Pregabalin 300 mg | Pregabalin 450 mg |
|---|---|---|---|---|---|---|
| Week 1 | 5.0 ± 4.10 | 18.8 ± 4.21 | 15.2 ± 4.10 | 15.9 ± 4.23 | 11.5 ± 4.16 | 17.2 ± 4.11 |
| Week 2 | 11.3 ± 4.10 | 23.3 ± 4.27 | 18.7 ± 4.13 | 24.2 ± 4.40 | 23.4 ± 4.20 | 24.0 ± 4.16 |
| Week 3 | 13.8 ± 4.17 | 23.0 ± 4.31 | 18.6 ± 4.10 | 26.8 ± 4.40 | 23.6 ± 4.20 | 25.4 ± 4.29 |
| Week 4 | 13.2 ± 4.14 | 23.8 ± 4.31 | 22.0 ± 4.10 | 28.2 ± 4.40 | 24.2 ± 4.20 | 23.8 ± 4.25 |
| Week 5 | 14.7 ± 4.17 | 28.7 ± 4.31 | 19.9 ± 4.10 | 30.9 ± 4.45 | 26.0 ± 4.20 | 31.1 ± 4.25 |
| Week 6 | 13.9 ± 4.17 | 27.6 ± 4.31 | 23.5 ± 4.14 | 30.5 ± 4.50 | 23.1 ± 4.20 | 28.8 ± 4.25 |
MOS-SS: subject-rated instrument used to assess the key constructs of sleep quantity and quality over the past week; comprised of 12 items yielding 7 subscale scores and 2 composite index scores. Sleep Disturbance Subscale score (4 items): range 0-100; lower score indicates less disturbance. Change from baseline = score at observation minus score at baseline.
| scores on scale | Placebo | Pregabalin 50 mg | Pregabalin 100 mg | Pregabalin 150 mg | Pregabalin 300 mg | Pregabalin 450 mg |
|---|---|---|---|---|---|---|
| Week 1 | -9.0 ± 4.76 | -18.2 ± 5.05 | -21.1 ± 4.87 | -23.0 ± 5.26 | -17.7 ± 4.93 | -26.3 ± 4.89 |
| Week 2 | -15.7 ± 4.76 | -25.1 ± 5.14 | -23.0 ± 4.81 | -26.1 ± 5.30 | -35.3 ± 4.95 | -32.1 ± 5.02 |
| Week 4 | -22.0 ± 4.81 | -18.5 ± 5.07 | -28.3 ± 4.76 | -32.4 ± 5.30 | -34.2 ± 4.95 | -37.4 ± 5.02 |
| Week 6 | -19.3 ± 4.87 | -29.2 ± 5.14 | -25.3 ± 4.81 | -33.4 ± 5.38 | -31.4 ± 4.95 | -40.2 ± 5.02 |
MOS-SS: subject-rated instrument used to assess the key constructs of sleep; assesses sleep quantity and quality over the past week. Comprised of 12 items yielding 7 subscale scores and 2 composite index scores. Snoring Subscale score (1 item): range 0-100, lower score indicates less snoring. Change from baseline = score at observation minus score at baseline.
| scores on scale | Placebo | Pregabalin 50 mg | Pregabalin 100 mg | Pregabalin 150 mg | Pregabalin 300 mg | Pregabalin 450 mg |
|---|---|---|---|---|---|---|
| Week 1 | -2.4 ± 5.39 | 5.2 ± 5.72 | -8.6 ± 5.53 | 0.7 ± 6.04 | -2.9 ± 5.46 | -9.2 ± 5.54 |
| Week 2 | -1.5 ± 5.39 | -0.8 ± 5.81 | -11.4 ± 5.47 | -8.7 ± 6.16 | -3.3 ± 5.48 | -12.2 ± 5.66 |
| Week 4 | -3.2 ± 5.44 | 4.4 ± 5.75 | -4.0 ± 5.42 | -7.5 ± 6.16 | 2.8 ± 5.48 | -3.5 ± 5.67 |
| Week 6 | -2.1 ± 5.50 | 2.5 ± 5.81 | -6.6 ± 5.47 | -2.0 ± 6.24 | 1.0 ± 5.48 | -7.5 ± 5.67 |
MOS-SS: subject-rated instrument used to assess the key constructs of sleep over the past week ; comprised of 12 items yielding 7 subscale scores and 2 composite index scores. Awaken Short of Breath or with Headache subscale score range: 0-100; lower score indicates less difficulty. Change from baseline = score at observation minus score at baseline.
| scores on scale | Placebo | Pregabalin 50 mg | Pregabalin 100 mg | Pregabalin 150 mg | Pregabalin 300 mg | Pregabalin 450 mg |
|---|---|---|---|---|---|---|
| Week 1 | -7.3 ± 3.49 | -1.7 ± 3.72 | -5.3 ± 3.62 | -9.2 ± 3.92 | -8.6 ± 3.51 | 1.4 ± 3.58 |
| Week 2 | -9.1 ± 3.49 | -4.3 ± 3.81 | -8.8 ± 3.54 | -12.1 ± 3.93 | -8.2 ± 3.53 | -1.1 ± 3.72 |
| Week 4 | -9.9 ± 3.56 | -2.5 ± 3.73 | -8.9 ± 3.47 | -9.9 ± 3.93 | -9.1 ± 3.53 | -9.2 ± 3.73 |
| Week 6 | -7.4 ± 3.63 | -0.9 ± 3.81 | -4.9 ± 3.54 | -11.5 ± 4.03 | -3.0 ± 3.53 | -8.2 ± 3.73 |
MOS-SS: subject-rated instrument used to assess the key constructs of sleep; assesses sleep quantity and quality and is comprised 12 items yielding 7 subscale scores and 2 composite index scores. Sleep Adequacy Subscale score range: 0-100; higher scores indicates greater sleep adequacy. Change from baseline = score at observation minus score at baseline.
| scores on scale | Placebo | Pregabalin 50 mg | Pregabalin 100 mg | Pregabalin 150 mg | Pregabalin 300 mg | Pregabalin 450 mg |
|---|---|---|---|---|---|---|
| Week 1 | 5.2 ± 5.38 | 16.1 ± 5.76 | 5.3 ± 5.53 | 13.7 ± 6.01 | 9.8 ± 5.50 | 16.1 ± 5.58 |
| Week 2 | 15.6 ± 5.38 | 31.0 ± 5.87 | 19.6 ± 5.45 | 21.9 ± 6.06 | 14.0 ± 5.53 | 29.5 ± 5.76 |
| Week 4 | 15.6 ± 5.45 | 23.9 ± 5.78 | 20.8 ± 5.38 | 24.7 ± 6.06 | 26.6 ± 5.53 | 34.6 ± 5.78 |
| Week 6 | 16.8 ± 5.54 | 34.6 ± 5.87 | 27.0 ± 5.45 | 26.8 ± 6.17 | 19.2 ± 5.53 | 31.1 ± 5.78 |
MOS-SS: subject-rated instrument used to assess the key constructs of sleep over the past week; assesses sleep quantity and quality and is comprised 12 items yielding 7 subscale scores and 2 composite index scores. Sleep Somnolence Subscale score range: 0-100; higher score indicates less somnolence. Change from baseline = score at observation minus score at baseline.
| scores on scale | Placebo | Pregabalin 50 mg | Pregabalin 100 mg | Pregabalin 150 mg | Pregabalin 300 mg | Pregabalin 450 mg |
|---|---|---|---|---|---|---|
| Week 1 | -7.4 ± 4.02 | -13.8 ± 4.29 | -9.8 ± 4.12 | -14.3 ± 4.46 | -11.2 ± 4.07 | -10.7 ± 4.14 |
| Week 2 | -13.9 ± 4.02 | -18.2 ± 4.36 | -11.1 ± 4.07 | -18.8 ± 4.49 | -11.3 ± 4.09 | -12.6 ± 4.25 |
| Week 4 | -14.0 ± 4.07 | -20.4 ± 4.30 | -11.8 ± 4.02 | -16.2 ± 4.49 | -16.9 ± 4.09 | -12.6 ± 4.26 |
| Week 6 | -11.7 ± 4.12 | -26.3 ± 4.36 | -14.8 ± 4.07 | -21.7 ± 4.56 | -13.4 ± 4.09 | -13.9 ± 4.26 |
MOS-SS: subject-rated instrument used to assess the key constructs of sleep over the past week; assesses sleep quantity and quality and is comprised 12 items yielding 7 subscale scores and 2 composite index scores. Sleep Quantity (1 item) subscale score range: 0-24 hours. Change from Baseline in number of hours slept. Change from baseline = score at observation minus score at baseline.
| scores on scale | Placebo | Pregabalin 50 mg | Pregabalin 100 mg | Pregabalin 150 mg | Pregabalin 300 mg | Pregabalin 450 mg |
|---|---|---|---|---|---|---|
| Week 1 | 0.4 ± 0.21 | 0.7 ± 0.22 | 0.5 ± 0.22 | 0.9 ± 0.23 | 0.4 ± 0.21 | 0.7 ± 0.22 |
| Week 2 | 0.5 ± 0.21 | 0.8 ± 0.23 | 0.6 ± 0.21 | 1.2 ± 0.23 | 0.7 ± 0.21 | 1.1 ± 0.22 |
| Week 4 | 0.6 ± 0.21 | 1.0 ± 0.22 | 0.7 ± 0.21 | 1.4 ± 0.23 | 1.1 ± 0.21 | 1.1 ± 0.22 |
| Week 6 | 0.6 ± 0.22 | 0.9 ± 0.23 | 0.7 ± 0.21 | 1.3 ± 0.24 | 0.7 ± 0.21 | 1.2 ± 0.22 |
MOS-SS: subject-rated instrument used to assess the key constructs of sleep over the past week; assesses sleep quantity and quality and is comprised 12 items yielding 7 subscale scores and 2 composite index scores. Sleep Problems Index I (6 items): composite index score range 0-100; lower score indicates fewer sleep problems. Change from baseline = score at observation minus score at baseline.
| scores on scale | Placebo | Pregabalin 50 mg | Pregabalin 100 mg | Pregabalin 150 mg | Pregabalin 300 mg | Pregabalin 450 mg |
|---|---|---|---|---|---|---|
| Week 1 | -9.2 ± 3.67 | -12.5 ± 3.91 | -10.4 ± 3.75 | -14.9 ± 4.06 | -13.9 ± 3.77 | -16.2 ± 3.77 |
| Week 2 | -14.8 ± 3.67 | -22.0 ± 3.97 | -15.7 ± 3.71 | -20.3 ± 4.09 | -20.1 ± 3.79 | -24.1 ± 3.87 |
| Week 4 | -17.2 ± 3.71 | -17.9 ± 3.92 | -19.6 ± 3.67 | -23.3 ± 4.09 | -24.4 ± 3.79 | -28.9 ± 3.88 |
| Week 6 | -15.5 ± 3.76 | -25.0 ± 3.97 | -21.1 ± 3.71 | -26.1 ± 4.15 | -18.8 ± 3.79 | -27.6 ± 3.88 |
MOS-SS: subject-rated instrument used to assess the key constructs of sleep over the past week; assesses sleep quantity and quality and is comprised 12 items yielding 7 subscale scores and 2 composite index scores. Composite index scores are sleep problems Index I (6 items) and sleep problems Index II (9 items). 9-Item Sleep Problems Index range: 0-100; lower score indicates fewer sleep problems. Change from baseline = score at observation minus score at baseline.
| scores on scale | Placebo | Pregabalin 50 mg | Pregabalin 100 mg | Pregabalin 150 mg | Pregabalin 300 mg | Pregabalin 450 mg |
|---|---|---|---|---|---|---|
| Week 1 | -8.1 ± 3.73 | -15.9 ± 3.96 | -14.2 ± 3.81 | -17.8 ± 4.12 | -14.4 ± 3.84 | -18.8 ± 3.83 |
| Week 2 | -15.5 ± 3.73 | -23.5 ± 4.03 | -19.0 ± 3.76 | -22.5 ± 4.15 | -23.3 ± 3.86 | -24.6 ± 3.93 |
| Week 4 | -18.2 ± 3.77 | -19.3 ± 3.98 | -22.0 ± 3.73 | -25.2 ± 4.15 | -27.0 ± 3.86 | -29.1 ± 3.93 |
| Week 6 | -16.8 ± 3.81 | -27.5 ± 4.03 | -22.2 ± 3.76 | -28.3 ± 4.21 | -22.3 ± 3.86 | -29.4 ± 3.93 |
MOS-SS: subject-rated instrument used to assess the key constructs of sleep over the past week; assesses sleep quantity and quality and is comprised 12 items yielding 7 subscale scores and 2 composite index scores. Optimal Sleep subscale is derived from sleep quantity average hours of sleep each night during the past week. Number of subjects with response: YES (Optimal) if sleep quantity was 7 or 8 hours of sleep per night.
| participants | Placebo | Pregabalin 50 mg | Pregabalin 100 mg | Pregabalin 150 mg | Pregabalin 300 mg | Pregabalin 450 mg |
|---|---|---|---|---|---|---|
| Week 1 | 6 | 10 | 7 | 9 | 6 | 11 |
| Week 2 | 8 | 6 | 11 | 9 | 12 | 12 |
| Week 4 | 11 | 12 | 11 | 10 | 14 | 11 |
| Week 6 | 12 | 11 | 11 | 10 | 9 | 13 |
RLS QoL: subject-rated instrument used to assess the impact of RLS on quality of life and health status function (symptom severity, daily activity, social functioning, sleep, concentrating and decision making, traveling, sexual activity, and work) yielding a summary score ranging from 0-100. Higher scores reflect better quality of life. Recall period is the month prior to the assessment. Change from baseline = score at observation minus score at baseline.
| scores on scales | Placebo | Pregabalin 50 mg | Pregabalin 100 mg | Pregabalin 150 mg | Pregabalin 300 mg | Pregabalin 450 mg |
|---|---|---|---|---|---|---|
| Restless Leg Syndrome - Quality of Life Scale (RLS-QoL): Change From Baseline to Week 6 | 15.0 ± 3.71 | 19.6 ± 3.87 | 22.4 ± 3.55 | 20.8 ± 3.94 | 15.9 ± 3.63 | 20.5 ± 3.74 |
Subject-rated measure of health status comprised of 36 items: 8 subscale scores (physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health), 2 summary scores (physical component and mental component), and a self-evaluated change in health status. Subscale and summary scores range: 0-100. Higher subscale and summary scores = better health status. Recall period: month prior to the assessment. Change from baseline = score at observation minus score at baseline.
| scores on scale | Placebo | Pregabalin 50 mg | Pregabalin 100 mg | Pregabalin 150 mg | Pregabalin 300 mg | Pregabalin 450 mg |
|---|---|---|---|---|---|---|
| Physical Functioning | 3.6 ± 3.50 | 0.5 ± 3.71 | 2.4 ± 3.42 | -0.4 ± 3.93 | 2.9 ± 3.52 | 3.6 ± 3.62 |
| Role-Physical | 1.1 ± 4.24 | 7.0 ± 4.49 | 7.5 ± 4.14 | 7.7 ± 4.77 | 0.9 ± 4.24 | 9.6 ± 4.40 |
| Bodily Pain | 6.9 ± 4.16 | 15.8 ± 4.41 | 12.9 ± 4.07 | 16.9 ± 4.87 | 13.3 ± 4.17 | 18.1 ± 4.31 |
| General Health | 6.5 ± 2.81 | 5.2 ± 3.05 | 4.0 ± 2.75 | 7.5 ± 3.15 | 3.6 ± 2.82 | 5.9 ± 2.90 |
| Vitality | 7.4 ± 3.98 | 11.1 ± 4.18 | 9.9 ± 3.86 | 18.5 ± 4.46 | 11.7 ± 3.95 | 13.9 ± 4.08 |
| Social Functioning | 7.8 ± 3.98 | 8.3 ± 4.20 | 4.8 ± 3.88 | 4.4 ± 4.47 | 9.5 ± 4.00 | 15.6 ± 4.10 |
| Role-Emotional | -2.1 ± 4.16 | 6.7 ± 4.38 | 7.8 ± 4.05 | 1.0 ± 4.63 | 8.1 ± 4.13 | 12.7 ± 4.31 |
| Mental Health | 2.9 ± 3.49 | 1.0 ± 3.68 | 3.6 ± 3.43 | 7.6 ± 3.90 | 3.7 ± 3.47 | 10.7 ± 3.59 |
| Summary Physical Score | 4.5 ± 2.83 | 7.4 ± 3.02 | 6.7 ± 2.77 | 8.2 ± 3.29 | 5.6 ± 2.85 | 9.7 ± 2.94 |
| Summary Emotional Score | 3.7 ± 3.33 | 6.9 ± 3.51 | 6.7 ± 3.24 | 8.2 ± 3.72 | 8.5 ± 3.32 | 13.5 ± 3.43 |
Subject-rated measure of health status comprised of 36 items: 8 subscale scores (physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health), 2 summary scores (physical component and mental component), and a self-evaluated change in health status. Self-evaluated change in health status: 5 Likert-type response categories ranging from "much worse now" to much better now." Recall period: month prior to the assessment.
| participants | Placebo | Pregabalin 50 mg | Pregabalin 100 mg | Pregabalin 150 mg | Pregabalin 300 mg | Pregabalin 450 mg |
|---|---|---|---|---|---|---|
| Baseline: Much Worse than 1 Year Ago | 0 | 3 | 1 | 2 | 3 | 2 |
| Baseline: Somewhat Worse than 1 Year Ago | 4 | 6 | 3 | 4 | 1 | 3 |
| Baseline: About the Same as 1 Year Ago | 15 | 9 | 15 | 14 | 14 | 12 |
| Baseline: Somewhat Better than 1 Year Ago | 2 | 1 | 3 | 0 | 5 | 2 |
| Baseline: Much Better than 1 Year Ago | 1 | 1 | 1 | 0 | 1 | 2 |
| Week 6: Much Worse than 1 Year Ago | 1 | 0 | 0 | 0 | 2 | 0 |
| Week 6: Somewhat Worse than 1 Year Ago | 2 | 3 | 2 | 4 | 3 | 1 |
| Week 6: About the Same as 1 Year Ago | 11 | 12 | 10 | 11 | 12 | 10 |
| Week 6: Somewhat Better than 1 Year Ago | 4 | 2 | 4 | 1 | 4 | 5 |
| Week 6: Much Better than 1 Year Ago | 3 | 2 | 6 | 1 | 2 | 4 |
Non-serious events are listed at a 1.45% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 0/23 (0%) | 13/23 (56.5%) |
| Pregabalin 50 mg | — | 1/22 (4.5%) | 9/22 (40.9%) |
| Pregabalin 100 mg | — | 0/23 (0%) | 12/23 (52.2%) |
| Pregabalin 150 mg | — | 0/22 (0%) | 15/22 (68.2%) |
| Pregabalin 300 mg | — | 0/24 (0%) | 17/24 (70.8%) |
| Pregabalin 450 mg | — | 0/23 (0%) | 19/23 (82.6%) |
| Event | Placebo | Pregabalin 50 mg | Pregabalin 100 mg | Pregabalin 150 mg | Pregabalin 300 mg | Pregabalin 450 mg |
|---|---|---|---|---|---|---|
| Gastric cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/23 | 1/22 | 0/23 | 0/22 | 0/24 | 0/23 |
| Event | Placebo | Pregabalin 50 mg | Pregabalin 100 mg | Pregabalin 150 mg | Pregabalin 300 mg | Pregabalin 450 mg |
|---|---|---|---|---|---|---|
| DizzinessNervous system disorders | 1/23 | 0/22 | 2/23 | 5/22 | 2/24 | 7/23 |
| SomnolenceNervous system disorders | 1/23 | 0/22 | 1/23 | 6/22 | 6/24 | 5/23 |
| HeadacheNervous system disorders | 3/23 | 5/22 | 2/23 | 2/22 | 4/24 | 2/23 |
| FatigueGeneral disorders | 0/23 | 0/22 | 4/23 | 2/22 | 1/24 | 2/23 |
| Abnormal dreamsPsychiatric disorders | 3/23 | 0/22 | 0/23 | 0/22 | 0/24 | 0/23 |
| Dry mouthGastrointestinal disorders | 0/23 | 0/22 | 0/23 | 1/22 | 3/24 | 2/23 |
| NauseaGastrointestinal disorders | 1/23 | 1/22 | 0/23 | 2/22 | 0/24 | 0/23 |
| Hot flushVascular disorders | 1/23 | 0/22 | 0/23 | 2/22 | 1/24 | 0/23 |
| Vision blurredEye disorders | 0/23 | 0/22 | 0/23 | 2/22 | 1/24 | 2/23 |
| Feeling drunkGeneral disorders | 0/23 | 0/22 | 0/23 | 0/22 | 1/24 | 2/23 |
| Age, Customized(participants) | Placebo | Pregabalin 50 mg | Pregabalin 100 mg | Pregabalin 150 mg | Pregabalin 300 mg | Pregabalin 450 mg | Total |
|---|---|---|---|---|---|---|---|
| 18 - 44 years | 4 | 5 | 7 | 2 | 9 | 3 | 30 |
| 45 - 64 years | 19 | 15 | 16 | 20 | 15 | 19 | 104 |
| >=65 years | 0 | 2 | 0 | 0 | 0 | 1 | 3 |
| Sex: Female, Male(Participants) | Placebo | Pregabalin 50 mg | Pregabalin 100 mg | Pregabalin 150 mg | Pregabalin 300 mg | Pregabalin 450 mg | Total |
|---|---|---|---|---|---|---|---|
| Female | 13 | 13 | 16 | 13 | 19 | 16 | 90 |
| Male | 10 | 9 | 7 | 9 | 5 | 7 | 47 |
The record gives a start of Apr 2008, a primary completion of Jan 2009 and a completion of Jan 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2010, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pregabalin
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. →